Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
535
datasets available to search
ShareScore release 0.9.0
Dataset results
535 results for “Neovascularization”
Genetic association analysis of anti-VEGF treatment response in neovascular age-related macular degeneration
<p>Summary statisics of an association study of 6,908,005 genetic variants with anti-VEGF nAMD treatment response in 179 treatment-naïve nAMD probands. This dataset supplements the publication "Genetic Association Analysis of Anti-VEGF Treatment Response in Neovascular Age-Related Macular Degeneration" (DOI: 10.3390/ijms23116094). Details regarding the methods and version numbers can be found in the corresponding manuscript.</p>
Therapeutic activation of endothelial sphingosine 1-phosphate receptor-1 by chaperone-bound S1P suppresses proliferative retinal neovascularization
<p>Sphingosine-1-phosphate (S1P), the circulating HDL-bound lipid mediator that acts via S1P receptors (S1PR), is required for normal vascular development. The role of this signaling axis in vascular retinopathies is unclear. Here we show in a mouse model of oxygen-induced retinopathy (OIR) that endothelial overexpression of <em>S1pr1</em> suppresses while endothelial knockout of <em>S1pr1</em> worsens neovascular tuft formation. Furthermore, neovascular tufts are increased in <em>Apom<sup>-/-</sup> </em>mice which lack HDL-bound S1P while they are suppressed in <em>Apom<sup>TG</sup> </em>mice which has more circulating HDL-S1P. These results suggest that circulating HDL-S1P activation of endothelial S1PR1 suppresses neovascular pathology in OIR. Additionally, systemic administration of ApoM-Fc-bound S1P or a small molecule Gi-biased S1PR1 agonist suppressed neovascular tuft formation. Circulating HDL-S1P activation of endothelial S1PR1 may be a key protective mechanism to guard against neovascular retinopathies that occur not only in premature infants but also in diabetes and aging.</p>
A Study to Assess the Effects of Brolucizumab in Adult Patients With Neovascular Age Related Macular Degeneration
ClinicalTrials.gov study NCT04239027. IPD Sharing: YES. Countries: 1. Publications: 1.
Study to Evaluate the Safety and Effectiveness of Intravitreal Injections (IVI) of Brolucizumab in Patients With Neovascular Age-related Macular Degeneration (nAMD)
ClinicalTrials.gov study NCT05269966. IPD Sharing: YES. Countries: 1. Publications: 16.
Efficacy and Safety of Two Different Brolucizumab 6 mg Dosing Regimens in Neovascular Age-related Macular Degeneration
ClinicalTrials.gov study NCT04679935. IPD Sharing: YES. Countries: 2. Publications: 1.
Study of Brolucizumab in Adult Patients With Suboptimal Anatomically Controlled Neovascular Age-related Macular Degeneration
ClinicalTrials.gov study NCT04264819. IPD Sharing: YES. Countries: 1. Publications: 1.
Analysis on Multimodal Imaging of 'stealth' Choroidal Neovascularization in Central Serous Chorioretinopathy
<p><strong>Purpose:</strong> To investigate the prevalence of concurrent choroidal neovascularization (CNV) in patients with clinically diagnosed of central serous chorioretinopathy (CSC) and analyze the multimodal imaging characteristics of CSC with ‘stealth’ CNV (CSC-sCNV). <strong>Design: </strong>Retrospective, observational cross-sectional study. <strong>Methods</strong><strong>:</strong> The current study analyzed the clinical data of 111 clinically diagnosed of CSC patients (134 eyes) who received fluorescein fundus angiography (FFA), indocyanine green angiography (ICGA), and optical coherence tomography angiography (OCTA) at their initial visit. The CSC-CNV that can be detected by FFA+ICG was defined as classic CSC-CNV (CSC-cCNV), and CSC-CNV that cannot be detected by FFA+ICG but can be detected by OCTA was defined as CSC-sCNV. The multimodal imaging characteristics of CSC-sCNV were analyzed.<strong> Results: </strong>The concurrent CNV was found in 29 eyes (21.6%) of 28 patients (25.2%), who were significantly older than those without CNV (P=0.039). Among the 29 eyes, 6 eyes (20.7%) were CSC-cCNV and 23 (79.3%) were CSC-sCNV. All CSC-sCNV eyes were type 1 CNV, of which, 22 had photoreceptor layer defects of varying severities. OCTA showed 4 (17.4%) were active CNV and 19 (82.6%) were inactive CNV based on the morphology features. CSC-sCNV lesions manifested as smoke-stack leakage, diffuse RPE changes with/without ink-blot leakage and normal fluorescence on FFA (1 eye, 7 eyes, 10 eyes and 5 eyes respectively). ICGA showed no typical CNV features in CSC-sCNV but choroidal vasodilation beneath CNV lesions and choroidal hyperpermeability at the posterior pole.<strong> Conclusion:</strong> CSC-sCNV may be the primary phenotype of CSC-CNV and its inactivity might be the reason that it cannot be detected by FFA.</p>
An Open Label Trial to Investigate Macugen for the Preservation of Visual Function in Subjects With Neovascular AMD
ClinicalTrials.gov study NCT00327470. IPD Sharing: Not stated. Countries: 15. Publications: 1.
A Proof-of-Concept Study of Faricimab (RO6867461) in Participants With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)
ClinicalTrials.gov study NCT02484690. IPD Sharing: Not stated. Countries: 1. Publications: 4.
A Study to Compare SB11 (Proposed Ranibizumab Biosimilar) to Lucentis in Subjects With Neovascular Age-related Macular Degeneration (AMD)
ClinicalTrials.gov study NCT03150589. IPD Sharing: NO. Countries: 9. Publications: 2.
Efficacy and Safety of Ranibizumab in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia
ClinicalTrials.gov study NCT01217944. IPD Sharing: Not stated. Countries: 20. Publications: 2.
Safety, Tolerability, and Efficacy of Aflibercept in Patients With Neovascular Age-Related Macular Degeneration
ClinicalTrials.gov study NCT04126317. IPD Sharing: YES. Countries: 2. Publications: 1.
Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration
ClinicalTrials.gov study NCT03038880. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A Study of the Criteria Establishing the Need for Re-treatment With Ranibizumab Upon Relapse in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia.
ClinicalTrials.gov study NCT02034006. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A Study in Patients With Neovascular Age Related Macular Degeneration or Macular Edema Secondary To Retinal Vein Occlusion to Evaluate Usability of the Ranibizumab (Lucentis®) Prefilled Syringe (PFS)
ClinicalTrials.gov study NCT02698566. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Treatment of Corneal Neovascularization With Topical Pazopanib
ClinicalTrials.gov study NCT01257750. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Efficacy and Safety of Two Treatment Regimens of 0.5 mg Ranibizumab Intravitreal Injections Guided by Functional and/or Anatomical Criteria, in Patients With Neovascular Age-related Macular Degenerati
ClinicalTrials.gov study NCT01780935. IPD Sharing: Not stated. Countries: 24. Publications: 1.
Efficacy and Safety of the Aflibercept FYB203 Biosimilar in Comparison to Eylea® in Patients With Neovascular Age-Related Macular Degeneration
ClinicalTrials.gov study NCT04522167. IPD Sharing: NO. Countries: 9. Publications: 1.
Ranibizumab in Hemorrhagic Choroidal Neovascularization Trial
ClinicalTrials.gov study NCT00363168. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Short-term Efficacy of Intravitreal Afilibercept Depending on Subtypes of Polypoidal Choroidal Vasculopathy: Polypoidal Choroidal Neovascularization or Idiopathic Choroidal Vasculopathy
ClinicalTrials.gov study NCT02597855. IPD Sharing: Not stated. Countries: 1. Publications: 1.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.